In Brief: Epitope OraSure
This article was originally published in The Gray Sheet
Executive Summary
Epitope OraSure: Oral sample-based HIV-1 antibody testing service for professional use is launched by marketing partner SmithKline Beecham Consumer Healthcare on August 5. SKBC believes the product "will replace blood as the medically preferred method for HIV testing," Gus Allen, Epitope VP-corporate communications, tells an Aug. 12 session of the Medical Investments Northwest conference in Seattle. The use of the product in the professional setting is expected to help generate information to support a marketing application for a home-use version ("The Gray Sheet" June 10, p. 4)...
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
England’s NICE Says No To Santhera’s DMD Drug Agamree Due To ‘Unreliable Modeling’
Santhera Pharmaceuticals did not provide enough evidence to demonstrate that its Duchenne muscular dystrophy drug Agamree was a cost-effective use of resources, according to draft guidance from England’s health technology assessment body, NICE.
Timely Acquisition Keeps Germany's Dermapharm Growing
With its Branded Pharmaceuticals division negatively impacted by the end of the COVID-19 pandemic, the timely acquisition of supplements firm Arkopharma ensured Dermapharm recorded double-digit sales growth in 2023.